4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists

doi:10.1016/0960-894X(96)00231-4

Bioorganic & Medicinal Chemistry Letters

Volume 6, Issue 12, 18 June 1996, Pages 1361-1366

https://doi.org/10.1016/0960-894X(96)00231-4 Get rights and content

Abstract

A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamide dopamine (DA) D₃ receptor agonists has been identified. These compounds were found to be selective for DA D₃ over D₂ receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D₃-transfected CHO p-5 cells.

A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamide dopamine (DA) D3 receptor agonists has been identified. These compounds were found to be selective for DA D3 over D2 receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D3-transfected CHO p-5 cells.

References (12)

E. Meller et al.
Eur. J. Pharmacol.
(1993)
T. Sokoloff et al.
Nature
(1990)
D. Rognan et al.
Chem. Abstr.
(1993)
T.A. Pugsley et al.
J. Pharmacol. Exp. Ther.
(1995)
T. Högberg
Drugs of the Future
(1991)

There are more references available in the full text version of this article.

Cited by (16)

Evaluation of N-phenyl homopiperazine analogs as potential dopamine D <inf>3</inf> receptor selective ligands
2013, Bioorganic and Medicinal Chemistry
Citation Excerpt :
Examples include BP 897, NGB 2904, and the structural congeners 1–5 (Fig. 1).18–20 A common structural feature of these conformationally-flexible benzamides is the N-arylpiperazine ring and the 4-carbon spacer group separating the benzamide and the piperazine moieties.18,21–25 The lipophilic residue on the arylamide moiety permits diverse modifications including aryl, biphenyl, heteroaryl, or cycloalkyl substituents.
A series of N-(2-methoxyphenyl)homopiperazine analogs was prepared and their affinities for dopamine D₂, D₃, and D₄ receptors were measured using competitive radioligand binding assays. Several ligands exhibited high binding affinity and selectivity for the D₃ dopamine receptor compared to the D₂ receptor subtype. Compounds 11a, 11b, 11c, 11f, 11j and 11k had K_i values ranging from 0.7 to 3.9 nM for the D₃ receptor with 30- to 170-fold selectivity for the D₃ versus D₂ receptor. Calculated log P values (log P = 2.6–3.6) are within the desired range for passive transport across the blood–brain barrier. When the binding and the intrinsic efficacy of these phenylhomopiperazines was compared to those of previously published phenylpiperazine analogues, it was found that (a) affinity at D₂ and D₃ dopamine receptors generally decreased, (b) the D₃ receptor binding selectivity (D₂:D₃ K_i value ratio) decreased and, (c) the intrinsic efficacy, measured using a forskolin-dependent adenylyl cyclase inhibition assay, generally increased.
The structural evolution of dopamine D<inf>3</inf> receptor ligands: Structure-activity relationships and selected neuropharmacological aspects
2006, Pharmacology and Therapeutics
“Evolution consists largely of molecular tinkering.”—Following the famous concept of the molecular geneticist and medicine Nobel laureate François Jacob, in this review we describe the structural evolution of dopamine D₃ receptor ligands from the natural agonist dopamine (DA) to highly potent and subtype selective new agents by bioisosteric tinkering with well-established and privileged or novel and fancy chemical functionalities and scaffolds. Some of the more than 200 ligands presented herein have already achieved therapeutic or scientific value up to now, some will most likely achieve it in the future. Hence, great importance is not only attached to the relationship between structure and activity of the ligands, but also to their utility as pharmacological tools in animal models or as therapeutics in patients with neurological diseases or other disorders.
Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D <inf>3</inf> receptor ligands
2005, Bioorganic and Medicinal Chemistry
A series of N-(2-methoxyphenyl)piperazine and N-(2,3-dichlorophenyl)piperazine analogs were prepared and their affinities for dopamine D₂, D₃, and D₄ receptors were measured in vitro. Binding studies were also conducted to determine if the compounds bound to sigma (σ₁ and σ₂) and serotonin (5-HT_1A, 5-HT_2A, 5-HT_2B, 5-HT_2C, 5-HT₃, 5-HT₄, 5-HT₅, 5-HT₆, and 5-HT₇) receptors. The results of the current study revealed a number of compounds (12b, 12c, 12e, and 12g) having a high affinity for D₃ (K_i at D₃ receptors ranging from 0.3 to 0.9 nM) versus D₂ (K_i at D₂ receptors ranging from 40 to 53 nM) receptors and a log P value indicating that they should readily cross the blood brain barrier (log P = 2.6–3.5). All of the compounds evaluated in this study had a high affinity for serotonin 5-HT_1A receptors. These compounds may be useful as probes for studying the behavioral pharmacology of the dopamine D₃ receptor, as well as lead compounds for the development of radiotracers for studying D₃ receptor regulation in vivo with the functional imaging technique, positron emission tomography.
Conformationally-flexible benzamide analogues as dopamine D<inf>3</inf> and σ<inf>2</inf> receptor ligands
2004, Bioorganic and Medicinal Chemistry Letters
A series of conformationally-flexible analogues was prepared and their affinities for D2-like dopamine (D₂, D₃ and D₄) were determined using in vitro radioligand binding assays. The results of this structure–activity relationship study identified one compound, 15, that bound with high affinity (K_i value=2 nM) and moderate selectivity (30-fold) for D₃ compared to D₂ receptors. In addition, this series of compounds were also tested for affinity at σ₁ and σ₂ receptors. We evaluated the affinity of these dopaminergic compounds at sigma receptors because (a) several antipsychotic drugs, which are high affinity antagonists at dopamine D_2-like receptors, also bind to sigma receptors and (b) sigma receptors are expressed ubiquitously and at high levels (picomoles per mg proteins). It was observed that a number of analogues displayed high affinity and excellent selectivity for σ₂ versus σ₁ receptors. Consequently, these novel compounds may be useful for characterizing the functional role of σ₂ receptors and for imaging the σ₂ receptor status of tumors in vivo with PET.
Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: Synthesis and dopamine receptor binding profiles
2000, Bioorganic and Medicinal Chemistry Letters
Phenylpiperazine derivatives with strong affinity for 5HT(1A), D(2A) and D<inf>3</inf> receptors
1998, Bioorganic and Medicinal Chemistry Letters

View all citing articles on Scopus

View full text

4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists

Abstract

Eur. J. Pharmacol.

Nature

Chem. Abstr.

J. Pharmacol. Exp. Ther.

Drugs of the Future

4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D₃ receptor partial agonists